NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)
Phase 2, Double-blind, Randomized, Placebo-controlled Study of NasoVAX in the Prevention of Clinical Worsening in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)
Sponsor: Altimmune, Inc.
Terminated
Enrollment
Other terminated trials from Altimmune, Inc.
More terminations from Altimmune, Inc.
Other Coronavirus Infection trials with similar outcome
A PHASE2 clinical study on Coronavirus Infection, this trial is terminated or withdrawn. The trial is conducted by Altimmune, Inc. and has accumulated 10 data snapshots since 2020. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
May 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Sep 2021 — May 2022 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Aug 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Altimmune, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .